Shopping Cart 0
Cart Subtotal
USD 0

Orexigen Therapeutics Inc (OREX)-Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Orexigen Therapeutics Inc (OREX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Orexigen Therapeutics Inc (Orexigen) is a biopharmaceutical company which develops and commercializes indications for the treatment of obesity. Its lead product, Contrave (naltrexone HCl / bupropion HCl prolonged release) is FDA approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults. Contrave is also approved in Europe under the brand name Mysimba. The company is also undertaking a range of commercialization activities, to bring Contrave / Mysimba to patients worldwide. The product is also sold in different countries worldwide through Orexigen's partners. The company is also undertaking a range of commercialization activities, to bring Contrave / Mysimba to patients worldwide. Orexigen is headquartered in La Jolla, California, the US.

Orexigen Therapeutics Inc Key Recent Developments

Mar 28,2017: Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016

Nov 03,2016: Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2016

Aug 04,2016: Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016

Jun 22,2016: Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 27,2016: Orexigen Therapeutics Founder and Former Chairman Eckard Weber Steps Down from Board

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Orexigen Therapeutics Inc-Key Facts 6

Orexigen Therapeutics Inc-Key Employees 7

Orexigen Therapeutics Inc-Key Employee Biographies 8

Orexigen Therapeutics Inc-Major Products and Services 9

Orexigen Therapeutics Inc-Pharmaceutical Pipeline Products Data 10

Orexigen Therapeutics Inc, Pipeline Products by Therapy Area 10

Orexigen Therapeutics Inc, Pipeline Products by Development Phase 11

Orexigen Therapeutics Inc-History 12

Orexigen Therapeutics Inc-Company Statement 15

Orexigen Therapeutics Inc-Locations And Subsidiaries 17

Head Office 17

Other Locations & Subsidiaries 17

Section 2-Company Analysis 18

Orexigen Therapeutics Inc-Business Description 18

Orexigen Therapeutics Inc-Corporate Strategy 19

Orexigen Therapeutics Inc-SWOT Analysis 20

SWOT Analysis-Overview 20

Orexigen Therapeutics Inc-Strengths 20

Orexigen Therapeutics Inc-Weaknesses 21

Orexigen Therapeutics Inc-Opportunities 22

Orexigen Therapeutics Inc-Threats 23

Orexigen Therapeutics Inc-Key Competitors 24

Section 3-Company Financial Ratios 25

Financial Ratios-Capital Market Ratios 25

Financial Ratios-Annual Ratios 26

Performance Chart 28

Financial Performance 28

Financial Ratios-Interim Ratios 29

Financial Ratios-Ratio Charts 30

Section 4-Company's Lifesciences Financial Deals and Alliances 31

Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31

Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32

Orexigen Therapeutics Inc, Recent Deals Summary 33

Section 5-Company's Recent Developments 34

Mar 28, 2017: Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 34

Nov 03, 2016: Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2016 36

Aug 04, 2016: Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016 38

Jun 22, 2016: Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 39

May 27, 2016: Orexigen Therapeutics Founder and Former Chairman Eckard Weber Steps Down from Board 40

May 23, 2016: Orexigen Appoints New Member of Board of Directors and Announces Senior Management Changes 42

May 04, 2016: Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016 43

Apr 25, 2016: Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth Eastland, Vice President of Sales, and Eight Additional New Employees 44

Feb 26, 2016: Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015 45

Jan 11, 2016: Orexigen announces 2016 financial outlook and key priorities 47

Section 6-Appendix 48

Methodology 48

Ratio Definitions 48

About GlobalData 52

Contact Us 52

Disclaimer 52


List Of Figure

List of Figures

Orexigen Therapeutics Inc, Pipeline Products by Therapy Area 10

Orexigen Therapeutics Inc, Pipeline Products by Development Phase 11

Orexigen Therapeutics Inc, Performance Chart (2012-2016) 28

Orexigen Therapeutics Inc, Ratio Charts 30

Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31

Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 32


List Of Table

List of Tables

Orexigen Therapeutics Inc, Key Facts 6

Orexigen Therapeutics Inc, Key Employees 7

Orexigen Therapeutics Inc, Key Employee Biographies 8

Orexigen Therapeutics Inc, Major Products and Services 9

Orexigen Therapeutics Inc, Number of Pipeline Products by Therapy Area 10

Orexigen Therapeutics Inc, Number of Pipeline Products by Development Stage 11

Orexigen Therapeutics Inc, History 12

Orexigen Therapeutics Inc, Subsidiaries 17

Orexigen Therapeutics Inc, Key Competitors 24

Orexigen Therapeutics Inc, Ratios based on current share price 25

Orexigen Therapeutics Inc, Annual Ratios 26

Orexigen Therapeutics Inc, Annual Ratios (Cont...1) 27

Orexigen Therapeutics Inc, Interim Ratios 29

Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 31

Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 32

Orexigen Therapeutics Inc, Recent Deals Summary 33

Currency Codes 48

Capital Market Ratios 48

Equity Ratios 49

Profitability Ratios 49

Cost Ratios 50

Liquidity Ratios 50

Leverage Ratios 51

Efficiency Ratios 51

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Orexigen Therapeutics Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Vivus Inc Novo Nordisk A/S GlaxoSmithKline Plc Genentech Inc Eisai Inc Arena Pharmaceuticals Inc